Last reviewed · How we verify
NCT00824356
A Randomised, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Assess the Efficacy and Safety of Single Dose Intranasal GSK1004723 Compared With Placebo in an Allergen Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis
Phase 2 trial testing GSK1004723 (200mg) in Allergic Rhinitis in 54 participants. Completed in 1 August 2008.
1 August 2008
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 54 |
| Start date | 1 June 2008 |
| Primary completion | 1 August 2008 |
| Estimated completion | 1 August 2008 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- GSK1004723 (200mg) — full drug profile →
- Placebo
- GSK1004723 (1000mg) — full drug profile →
Conditions studied
- Allergic Rhinitis — all drugs for Allergic Rhinitis →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
Adults 18 to 65, male only, with Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Change from baseline in total nasal symptom score 0-4 hours post dose
Time frame: 0-4 hours post dose
Sponsor's own description
This is a placebo-controlled, 3-period crossover study to assess the efficacy and safety of two single doses of an intranasal anti-histamine GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New antihistamines - perspectives in the treatment of some allergic and inflammatory disorders.
Tatarkiewicz J, Rzodkiewicz P, Żochowska M, Staniszewska A, et al · · 2019 · cited 19× · PMID 30899308 · DOI 10.5114/aoms.2017.68534
Verify or expand the search:
- PubMed search for NCT00824356
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allergic Rhinitis
Currently open trials in the same condition.
- NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
- NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
- NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
- NCT07455968 — Free Diving Breathing Training in Allergic Rhinitis · NA · active not recruiting
- NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis · NA · recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00824356 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 18 June 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00824356.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing